A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
Journal
Clinical Cancer Research
Journal Volume
20
Journal Issue
23
Pages
5976-5985
Date Issued
2014
Author(s)
Lim H.Y.
Heo J.
Choi H.J.
Lin C.-Y.
Yoon J.-H.
Rau K.-M.
Poon R.T.P.
Yeo W.
Park J.-W.
Tay M.H.
Hsieh W.-S.
Kappeler C.
Rajagopalan P.
Krissel H.
Jeffers M.
Yen C.-J.
Tak W.Y.
Publisher
American Association for Cancer Research Inc.
Type
journal article